ArticleBMC cancer2025
Pan-cancer analysis of tumor suppressor ZNF132 reveals its diagnostic and prognostic significance with immunomodulatory implications in colorectal cancer.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prognostic value of neuro-related genes in colorectal cancer and their potential implications for immunotherapy.Journal of Cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZinc finger protein 132 (ZNF132) has emerged as a potential tumor suppressor, with its dysregulation closely associated with the initiation and progression of various malignancies. However, a comprehensive assessment of ZNF132's expression patterns across diverse cancer types, its clinical prognostic implications, and its immunoregulatory role in colorectal cancer remains insufficiently characterized. This study aims to elucidate the biological functions of ZNF132 within the context of colorectal cancer.
methodsWe utilized transcriptomic data from 33 cancer types obtained from The Cancer Genome Atlas (TCGA) and the TCGA-COADREAD dataset to systematically analyze the expression characteristics of ZNF132 and its differential expression in colorectal cancer. Validation of protein expression was conducted using data from the Human Protein Atlas (HPA). The relationship between ZNF132 and immune infiltration was examined through single-sample gene set enrichment analysis (ssGSEA) and Spearman correlation analysis. We evaluated the diagnostic, prognostic, and independent risk prediction capabilities of ZNF132 using receiver operating characteristic (ROC) curves, Kaplan-Meier survival analysis, and multivariable Cox regression models. Additionally, we explored the biological pathways associated with ZNF132-related differentially expressed genes through Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA), supplemented by in vitro experiments to investigate the functional roles of ZNF132 in colorectal cancer.
resultsPan-cancer analysis demonstrated a significant downregulation of ZNF132 in colorectal and rectal cancers, accompanied by reduced protein levels in colorectal cancer tissues. Immune infiltration analysis revealed significant correlations between ZNF132 and various immune cell subtypes in colorectal cancer, notably a negative correlation with Th17 cells and NK CD56bright cells, while exhibiting positive correlations with T helper cells, central memory T cells, macrophages, and Th2 cells. The expression of ZNF132 was significantly associated with clinical pathological features in colorectal cancer patients, including age, M stage, and pathological grade. ROC curve analysis indicated that ZNF132 possesses high sensitivity and specificity for colorectal cancer diagnosis (AUC = 0.845). Kaplan-Meier analysis further confirmed that elevated ZNF132 expression correlates with extended survival in colorectal cancer patients. Multivariable Cox regression analysis identified ZNF132 as an independent risk factor for overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) in these patients. Enrichment analysis suggested that ZNF132 modulates tumor progression by influencing calcium signaling, PPAR pathways, and apoptosis-related genes. Functional assays demonstrated that ZNF132 significantly inhibits the proliferation, migration, and invasion of colorectal cancer cells.
conclusionZNF132 functions as a novel tumor suppressor, influencing colorectal cancer progression through the regulation of the immune microenvironment and malignant cellular phenotypes. Its diagnostic and prognostic potential offers new therapeutic targets for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.